Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below 200 Day Moving Average – Here’s Why

Predictive Oncology Inc. (NASDAQ:POAI)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $7.86 and traded as low as $1.69. Predictive Oncology shares last traded at $1.83, with a volume of 41,146 shares trading hands.

Analysts Set New Price Targets

Separately, Wall Street Zen cut Predictive Oncology to a “strong sell” rating in a report on Saturday, December 6th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Predictive Oncology Trading Up 5.5%

The stock’s fifty day simple moving average is $3.85 and its 200 day simple moving average is $7.78. The company has a market cap of $6.19 million, a price-to-earnings ratio of -0.14 and a beta of 1.35.

About Predictive Oncology

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.